Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/27/2021 | Sell → Hold | Gabelli & Co. | |
7/26/2021 | Buy → Neutral | HC Wainwright & Co. |
Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has commenced its previously disclosed rights offering (the "Rights Offering"). Pursuant to the Rights Offering, the Company is distributing, at no charge, subscription rights to the Company's shareholders and holders of warrants that have contractual rights to participate in the Rights Offering which have not been waived (each, an "eligible warrant" and collectively, the "eligible warrants") as of 5:00 p.m., E
HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.
DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical development and regulatory initiatives for Iterum. "We are thrilled that Sailaja is back at Iterum given her strong industry and operational leadership at a time when oral sulopenem is re-entering the clin
Patrick Heron to leave the Board DUBLIN, Ireland and CHICAGO, March 16, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Beth P. Hecht to the Company’s Board of Directors replacing Patrick Heron, who announced he would be leaving the Board, effective as of March 12, 2021. Ms. Hecht will also serve as a member of the Audit Committee and Compensation Committee of the Board. “I want to thank Patrick for his leade
8-K - Iterum Therapeutics plc (0001659323) (Filer)
424B5 - Iterum Therapeutics plc (0001659323) (Filer)
424B5 - Iterum Therapeutics plc (0001659323) (Filer)
SC 13G - Iterum Therapeutics plc (0001659323) (Subject)
SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)
SC 13D/A - Iterum Therapeutics plc (0001659323) (Subject)
4 - Iterum Therapeutics plc (0001659323) (Issuer)
4 - Iterum Therapeutics plc (0001659323) (Issuer)
4 - Iterum Therapeutics plc (0001659323) (Issuer)
Monday, October 28, 2024, at 8:30 a.m. EDT DUBLIN and CHICAGO, Oct. 28, 2024 /PRNewswire/ -- WHO: Iterum Therapeutics plc (NASDAQ:ITRM) is focused on deliveringdifferentiated anti-infectives aimed at combatting the global crisis of multi-drugresistant pathogens to significantly improve the lives of people affected byserious and life-threatening diseases around the world. WHAT: Conference call to discuss U.S. Food and Drug Administration (FDA) approval ofIterum's ORLYNVAH™ (Oral Sulopenem) for the treatment of uncomplicatedurinary tract infections (uUTIs).Speakers include: Co
ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades --Company to Host Conference Call on Monday, October 28th at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Iterum), today announced that the U.S. Food and Drug Administration (FDA) has approved Iterum's new drug application for ORLYNVAH™ (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alter
DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at the Infectious Disease Society of America's IDWeek 2024 conference taking place in Los Angeles, CA from October 16-19, 2024. Data to be presented at IDWeek 2024 include: Presentation Title: Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE TrialPoster #: 1107Presenter: Stev
Gabelli & Co. upgraded Iterum Therapeutics from Sell to Hold
HC Wainwright & Co. downgraded Iterum Therapeutics from Buy to Neutral
Gabelli & Co upgraded Iterum Therapeutics from Sell to Hold
4 - Iterum Therapeutics plc (0001659323) (Issuer)
4 - Iterum Therapeutics plc (0001659323) (Issuer)
4 - Iterum Therapeutics plc (0001659323) (Issuer)
Monday, October 28, 2024, at 8:30 a.m. EDT DUBLIN and CHICAGO, Oct. 28, 2024 /PRNewswire/ -- WHO: Iterum Therapeutics plc (NASDAQ:ITRM) is focused on deliveringdifferentiated anti-infectives aimed at combatting the global crisis of multi-drugresistant pathogens to significantly improve the lives of people affected byserious and life-threatening diseases around the world. WHAT: Conference call to discuss U.S. Food and Drug Administration (FDA) approval ofIterum's ORLYNVAH™ (Oral Sulopenem) for the treatment of uncomplicatedurinary tract infections (uUTIs).Speakers include: Co
ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades --Company to Host Conference Call on Monday, October 28th at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Iterum), today announced that the U.S. Food and Drug Administration (FDA) has approved Iterum's new drug application for ORLYNVAH™ (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alter
-- FDA PDUFA Action Date of October 25, 2024; Advisory Committee Meeting on September 9, 2024— --Cash Runway into 2025, including through PDUFA Action Date-- --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), (Iterum) a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2024. "We are pleased to have recently closed our rights offering, the proceeds of which all